What is HC Wainwright’s Estimate for Genmab A/S Q4 Earnings?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – HC Wainwright lifted their Q4 2025 earnings per share (EPS) estimates for Genmab A/S in a research note issued to investors on Wednesday, January 28th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.51 per share for the quarter, up from their previous estimate of $0.40. HC Wainwright has a “Buy” rating and a $39.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.46 EPS and FY2026 earnings at $1.68 EPS.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.17. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $975.40 million.

Several other analysts have also issued reports on GMAB. Zacks Research lowered shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Wall Street Zen raised shares of Genmab A/S from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Finally, Truist Financial reissued a “buy” rating and set a $48.00 price target (down previously from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.25.

Genmab A/S Stock Performance

Shares of GMAB opened at $32.63 on Friday. The firm has a market cap of $20.96 billion, a P/E ratio of 13.89, a price-to-earnings-growth ratio of 19.53 and a beta of 0.90. The business has a 50-day moving average of $32.47 and a 200 day moving average of $29.05. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $35.43.

Hedge Funds Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently made changes to their positions in the company. Alliancebernstein L.P. increased its holdings in Genmab A/S by 2.7% in the 3rd quarter. Alliancebernstein L.P. now owns 10,953,913 shares of the company’s stock worth $335,957,000 after buying an additional 291,538 shares during the period. Orbis Allan Gray Ltd raised its position in shares of Genmab A/S by 38.7% during the 2nd quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock worth $163,635,000 after purchasing an additional 2,209,659 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new position in shares of Genmab A/S in the third quarter valued at approximately $117,063,000. Arrowstreet Capital Limited Partnership lifted its holdings in Genmab A/S by 5.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,643,139 shares of the company’s stock valued at $111,735,000 after purchasing an additional 188,761 shares in the last quarter. Finally, First Trust Advisors LP lifted its stake in shares of Genmab A/S by 3.5% in the second quarter. First Trust Advisors LP now owns 1,770,310 shares of the company’s stock worth $36,575,000 after buying an additional 60,504 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S News Roundup

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $39 target while raising FY2025 estimates (now $2.00 EPS) and some near‑term quarter forecasts, providing support under the stock. HC Wainwright Reiterates “Buy” Rating for Genmab A/S (NASDAQ:GMAB)
• Neutral Sentiment: Genmab disclosed grants of 32,806 restricted stock units and 34,307 warrants to employees — normal for biotech compensation but potentially modestly dilutive if exercised; not likely to be a major near‑term earnings driver. Grant of Restricted Stock Units and Warrants to Employees in Genmab
• Neutral Sentiment: Reported short‑interest data for January appears to show no meaningful or reliable change (entries show zero/NaN), so short covering is not a clear factor in today’s move.
• Negative Sentiment: HC Wainwright cut multiple 2026 quarterly and full‑year EPS forecasts: FY2026 now $1.68 (was $2.14); Q4 2026 to $0.46 (from $0.63); Q1 2026 to $0.27 (from $0.34); Q2 2026 to $0.49 (from $0.58); Q3 2026 to $0.47 (from $0.59). Those downgrades lower near‑term earnings visibility and are the primary reason investors are marking the stock down today.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.